PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
May 29, 2026Journal of Clinical Oncology

Real-world treatment patterns and overall survival in recurrent/metastatic head and neck squamous cell carcinoma following treatment with immune checkpoint inhibitor and platinum-based chemotherapy.

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAri J. RosenbergATAmy (Xiaoqin) TangABArchan Bhattacharya

Discussion

Loading...

Member takes

Overview

Retrospective analysis of treatment outcomes in recurrent/metastatic head and neck cancer reveals poor survival rates, highlighting the need for new therapies.

Key Points

  • To characterize treatment patterns and survival outcomes in patients with recurrent/metastatic head and neck squamous cell carcinoma following treatment with immune checkpoint inhibitors and platinum-based chemotherapy.
  • Retrospective analysis of electronic medical records from the Flatiron Health database.
  • Included patients with recurrent/metastatic HNSCC treated prior with PD-1 inhibitor and platinum-based chemotherapy.
  • Descriptive analysis of demographics, treatment patterns, and overall survival using Kaplan-Meier method.
  • Identified 2105 patients, with 834 eligible for analysis after initial treatments.
  • Median overall survival was 7.8 months (95% CI, 7.0–8.4), longer for HPV-related (9.3 months) than HPV-unrelated (6.8 months) disease.
  • 39% of HPV-related and 49% of HPV-unrelated patients died before receiving subsequent therapy.

Cite This Study

Rosenberg et al. (2026) studied this question.

synapsesocial.com/papers/6a192eb9fab5b468c4417ed1https://doi.org/10.1200/jco.2026.44.16_suppl.6038
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Survival outcomes of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with platinum-based chemotherapy plus paclitaxel after anti-PD-1 monotherapy.2024
  2. 2Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data.2024 · 2 citations
  3. 3Assessment of drug utilization patterns and associated survival outcomes in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Insights from a resource-constrained set-up2026
  4. 4Combination Therapy of Anti-PD-1 Immunotherapy and Taxanes in Relapsed and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Real-world Single-center Retrospective Study2026
  5. 5Treatment with (chemo)-radiation in old patients (≥76 years of age) with newly diagnosed non-metastatic squamous cell cancer of the head and neck region: real-world data from a tertiary referral center2024